CureVac N.V. (CVAC)
NASDAQ: CVAC · Real-Time Price · USD
5.39
+0.04 (0.75%)
At close: Sep 5, 2025, 4:00 PM
5.39
0.00 (0.00%)
After-hours: Sep 5, 2025, 4:00 PM EDT
CureVac Revenue
CureVac had revenue of 1.25M EUR in the quarter ending June 30, 2025, a decrease of -91.38%. This brings the company's revenue in the last twelve months to 510.51M, up 675.15% year-over-year. In the year 2024, CureVac had annual revenue of 535.18M with 895.54% growth.
Revenue (ttm)
510.51M EUR
Revenue Growth
+675.15%
P/S Ratio
2.02
Revenue / Employee
519,338 EUR
Employees
983
Market Cap
1.21B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 535.18M | 481.42M | 895.54% |
| Dec 31, 2023 | 53.76M | -13.66M | -20.26% |
| Dec 31, 2022 | 67.42M | -35.57M | -34.54% |
| Dec 31, 2021 | 102.99M | 54.12M | 110.74% |
| Dec 31, 2020 | 48.87M | 31.46M | 180.61% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
CVAC News
- 21 days ago - CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates - Accesswire
- 4 weeks ago - CureVac settles patent dispute litigation with Pfizer and BioNTech - Reuters
- 2 months ago - CureVac Announces Voting Results of General Meeting - Accesswire
- 3 months ago - Top Stock Movers Now: Oracle, Boeing, CureVac, and More - Investopedia
- 3 months ago - BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal - Benzinga
- 3 months ago - BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising. - Barrons
- 3 months ago - BioNTech to acquire CureVac in $1.25 billion all-stock deal - Reuters
- 3 months ago - CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates - Accesswire